Patient information: uses, side effects, how to take - Hemlibra
What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment.
HEMLIBRA may cause the following serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including:
- Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
- confusion
- weakness
- swelling of arms and legs
- yellowing of skin and eyes
- stomach (abdomen) or back pain
- nausea or vomiting
- feeling sick
- decreased urination
- Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung, or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
- swelling in arms or legs
- pain or redness in your arms or legs
- shortness of breath
- chest pain or tightness
- fast heart rate
- cough up blood
- feel faint
- headache
- numbness in your face
- eye pain or swelling
- trouble seeing
If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.
Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (e.g., increase in bleeds).
See "What are the possible side effects of HEMLIBRA?" for more information about side effects.
What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.
Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.
HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.
Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:
are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
- are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use HEMLIBRA?
See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
- Use HEMLIBRA exactly as prescribed by your healthcare provider.
- Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.
- You may continue prophylactic use of FVIII for the first week of HEMLIBRA prophylaxis.
- HEMLIBRA is given as an injection under your skin (subcutaneous injection) by you or a caregiver.
- Your healthcare provider should show you or your caregiver how to prepare, measure, and inject your dose of HEMLIBRA before you inject yourself for the first time.
- Do not attempt to inject yourself or another person unless you have been taught how to do so by a healthcare provider.
- Your healthcare provider will prescribe your dose based on your weight. If your weight changes, tell your healthcare provider.
- You will receive HEMLIBRA 1 time a week for the first four weeks. Then you will receive a maintenance dose as prescribed by your healthcare provider.
- If you miss a dose of HEMLIBRA on your scheduled day, you should give the dose as soon as you remember. You must give the missed dose as soon as possible before the next scheduled dose, and then continue with your normal dosing schedule. Do not give two doses on the same day to make up for a missed dose.
- HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.
What are the possible side effects of HEMLIBRA?
- See " What is the most important information I should know about HEMLIBRA?"
The most common side effects of HEMLIBRA include:
- redness, tenderness, warmth, or itching at the site of injection
- headache
- joint pain
These are not all of the possible side effects of HEMLIBRA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store HEMLIBRA?
- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- If needed, unopened vials of HEMLIBRA can be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator for more than a total of 7 days or at a temperature greater than 86°F (30°C).
- After HEMLIBRA is transferred from the vial to the syringe, HEMLIBRA should be used right away.
- Throw away (dispose of) any unused HEMLIBRA left in the vial.
Keep HEMLIBRA and all medicines out of the reach of children.
General information about the safe and effective use of HEMLIBRA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.
What are the ingredients in HEMLIBRA?
Active ingredient: emicizumab-kxwh
Inactive ingredients: L-arginine, L-histidine, poloxamer 188, and L-aspartic acid.
Manufactured by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No. 1048
HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
©2025 Genentech, Inc. All rights reserved.
For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
Instructions for Use
HEMLIBRA® (hem-lee-bruh)
(emicizumab-kxwh)
injection, for subcutaneous use

Be sure that you read, understand, and follow this Instructions for Use before injecting HEMLIBRA. Your healthcare provider should show you or your caregiver how to prepare, measure, and inject HEMLIBRA properly before you use it for the first time. Ask your healthcare provider if you have any questions.
Important Information:
- Do not inject yourself or someone else unless you have been shown how to by your healthcare provider.
- Make sure the name HEMLIBRA appears on the box and vial label.
- Before opening the vial, read the vial label to make sure you have the medicine strength(s) needed to give the dose prescribed by your healthcare provider.
- Your healthcare provider will determine your dose in milliliters (mL) that you will need to give based on your body weight.
- HEMLIBRA comes in multiple strengths. Depending on your dose, you may need to use more than one vial to give your total prescribed dose. Do not combine HEMLIBRA vials of different concentrations in one injection to give the prescribed dose.
- Check the expiration date on the box and vial label. Do not use if the expiration date has passed.
- Only use the vial one time. After you inject your dose, dispose of (throw away) any unused HEMLIBRA left in the vial. Do not save unused HEMLIBRA in the vial for later use.
- Only use the syringes, transfer needles, and injection needles that your healthcare provider prescribes.
- Only use the syringes, transfer needles and injection needles one time. Dispose of (throw away) any used syringes and needles in a sharps disposal container.
- If your prescribed dose is more than 2 mL, you will need to give more than one injection of HEMLIBRA.
Storing HEMLIBRA:
- Store HEMLIBRA in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
- Store HEMLIBRA in the original carton to protect the vials from light.
- Do not shake HEMLIBRA.
- Take the vial out of the refrigerator 15 minutes before use and allow it to reach room temperature before preparing an injection.
Before giving the injection, unopened vials of HEMLIBRA may be stored out of the refrigerator and then returned to the refrigerator. HEMLIBRA should not be stored out of the refrigerator:
- for more than a total of 7 days or
- at a temperature greater than 86°F (30°C).
Keep HEMLIBRA and all medicines out of the reach of children.
Inspecting the HEMLIBRA vial and your supplies:
- Collect all supplies listed below to prepare and give your injection.
- Check the expiration date on the box, on the vial label, and on the supplies listed below. Do not use if the expiration date has passed.
- Inspect the supplies for damage. Do not use if they appear damaged or if they have been dropped.
- Place the supplies on a clean, well-lit flat work surface.
HEMLIBRA is colorless to slightly yellow in color. Do not use the vial if:
- the medicine is cloudy, hazy, or colored.
- the medicine contains particles.
- the cap covering the stopper is missing.
| Included in the box: | ||
![]() |
| |
![]() |
| |
| Not included in the box: | ||
![]() |
| |
![]() |
| |
![]() |
| |
![]() |
| |
![]() |
| |
Get ready:
| ![]() |
| Selecting and preparing an injection site: | |
| ![]() |
Preparing the syringe for injection:
- HEMLIBRA must not be stored in the syringe.
- HEMLIBRA in the syringe must be injected under the skin (subcutaneous injection) immediately.
- Dispose of (throw away) any used vial(s), needles, vial and injection needle caps, and used syringes in a sharps disposal container.
Important information after the injection:
- Do not rub the injection site after an injection.
- If you see drops of blood at the injection site, you can press a sterile cotton ball or gauze over the injection site for at least 10 seconds, until bleeding has stopped.
- If you have bruising (small area of bleeding under the skin), an ice pack can also be applied with gentle pressure to the site. If bleeding does not stop, please contact your healthcare provider.
Disposing of used HEMLIBRA vial(s), needles, and syringes:
- Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not dispose of (throw away) any loose needles and syringes in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
- made of heavy-duty plastic.
- can be closed with a tight-fitting, puncture resistant lid, without sharps being able to come out.
- upright and stable during use.
- leak-resistant.
- properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
- Do not dispose of (throw away) any used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Important: Always keep the sharps disposal container out of reach of children.
1. PREPARATION
| Step 1. Remove vial cap and clean top | |
![]() |
|
![]() |
|
| Step 2. Attach transfer needle with filter to syringe | |
![]() |
|
![]() |
|
| Step 3. Uncap transfer needle | |
![]() |
|
| Step 4. Inject air into vial | |
![]() |
|
![]() |
|
![]() |
|
| Step 5. Transfer HEMLIBRA to syringe | |
![]() |
|
| Important: If your prescribed dose is more than the amount of HEMLIBRA in the vial, withdraw all HEMLIBRA and go to the " Combining Vials " section now. | |
| Step 6. Remove air bubbles | |
![]() ![]() |
|
| Note: Ensure you have enough HEMLIBRA in the syringe to complete your dose before moving on to the next step. If you cannot remove all of HEMLIBRA, turn the vial upright to reach the remaining amount. |
Do not use the transfer needle to inject HEMLIBRA as this may cause harm such as pain and bleeding.
2. INJECTION
| Step 7. Recap transfer needle | |
![]() |
|
| Step 8. Clean injection site | |
![]() |
|
| Step 9. Remove transfer needle | |
![]() |
|
| Step 10. Attach injection needle to syringe | |
![]() |
|
| Step 11. Move safety shield | |
![]() |
|
| Step 12. Uncap injection needle | |
![]() |
|
| Step 13. Adjust plunger to prescribed dose | |
![]() |
|
| Step 14. Subcutaneous (under the skin) injection | |
![]() |
|
| Step 15. Inject HEMLIBRA | |
![]() |
|
3. DISPOSAL
| Step 16. Cover needle with safety shield | |
![]() |
|
![]() |
|
| Step 17. Dispose of (throw away) the used HEMLIBRA vial(s), needle, and syringe | |
![]() |
|
| Combining Vials |
If you need to use more than one vial to get to your total prescribed dose, follow these steps after you have drawn up HEMLIBRA from the first vial:
| Step A. Recap transfer needle | |
![]() |
|
| Step B. Remove transfer needle | |
![]() |
|
| Step C. Attach a new transfer needle with filter to syringe | |
![]() | Note: You must use a new transfer needle with filter each time you withdraw HEMLIBRA from a new vial.
|
| Step D. Uncap transfer needle | |
![]() |
|
| Step E. Inject air into vial | |
![]() |
|
![]() |
|
![]() |
|
| Step F. Transfer HEMLIBRA to syringe | |
![]() |
|
| Note: Ensure you have enough HEMLIBRA in the syringe to complete your dose before moving onto the next steps. If you cannot remove all of HEMLIBRA, turn the vial upright to reach the remaining amount. |
Do not use the transfer needle to inject HEMLIBRA as this may cause harm such as pain and bleeding.
| Repeat steps A to F with each additional vial until you have more than the amount of HEMLIBRA needed for your prescribed dose. Once completed, keep the transfer needle inserted in the vial and return to Step 6. Continue with the remaining steps. |
For more information, go to www.HEMLIBRA.com or call 1-866-HEMLIBRA.
HEMLIBRA® [emicizumab-kxwh]
Manufactured by:
Genentech, Inc.
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080-4990
HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
©2023 Genentech, Inc. All rights reserved.
U.S. License No. 1048
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: 07/2023








































